logo
Plus   Neg
Share
Email

Devon Energy Posts Q4 Loss

Devon Energy Corp. (DVN) Tuesday reported fourth-quarter net loss of $642 million or $1.70 per share, compared to net income of $1.15 billion or $2.48 per share last year.

Excluding items, Devon Energy reported adjusted earnings of $128 million or $0.33 per share for the period. Analysts polled by Thomson Reuters estimated earnings of $0.32 per share. Analysts estimates typically exclude one-time items.

Revenues for the quarter rose to $1.59 billion from $3.53 billion last year. Analysts had a consensus revenue estimate of $1.85 billion.

Moving ahead, the company raised its full-year 2020 oil growth rate to range of 7.5% to 9%. In the first-quarter 2020, oil production is projected to average in
the range of 158,000 to 163,000 barrels per day.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT